Afatinib medical insurance indications and reimbursement policy explanation

Afatinib (Afatinib) is an irreversible ErbB family tyrosine kinase inhibitor. For the treatment of patients with advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). In China, afatinib has been launched and included in the coverage of medical insurance, providing financial support to patients who meet the indications and reducing the burden of treatment.

The medical insurance indications mainly include patients with EGFR mutation-positive advanced non-small cell lung cancer, especially patients with common exon 19 deletions or 21 exon L858R mutations. Eligible patients can obtain afatinib at the hospital based on a doctor's prescription and through medical insurance reimbursement, thereby reducing patients' out-of-pocket costs and improving drug accessibility.

In terms of reimbursement policies, specific reimbursement ratios and procedures will vary from region to region. Usually, patients need to purchase medicines at medical insurance designated pharmacies or hospital pharmacies with a prescription issued by a doctor and relevant examination certificates. Some areas may require outpatient reimbursement for special diseases or accounting based on annual limits. Therefore, patients are recommended to consult local hospitals and pharmacies in detail before taking medication to understand the latest policies and reimbursement conditions.

For foreign markets, afatinib is available as original drug and generic drug. The price of the original version in India is about more than 5,000 yuan, while the price of generic drugs, including the Indian, Laos and Bangladeshi versions, is more affordable, ranging from a few hundred to more than 2,000 yuan. It is worth noting that whether it is an original drug or a generic drug, the drug ingredients are basically the same, and patients can make reasonable choices based on their economic status and availability.

Reference materials:https://www.drugs.com/